Get the Stockscreener App
26.48
1.85%
0.48
After Hours:
26.51
0.03
+0.11%
Xoma Royalty Corp stock is traded at $26.48, with a volume of 17,923.
It is up +1.85% in the last 24 hours and down -9.47% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
See More
Previous Close:
$26.00
Open:
$26.4
24h Volume:
17,923
Relative Volume:
0.70
Market Cap:
$306.77M
Revenue:
$4.76M
Net Income/Loss:
$-40.83M
P/E Ratio:
-9.8439
EPS:
-2.69
Net Cash Flow:
$-18.16M
1W Performance:
-2.25%
1M Performance:
-9.47%
6M Performance:
+10.10%
1Y Performance:
+87.93%
1-Day Range:
$26.15
$27.52
1-Week Range:
$25.33
$27.57
52-Week Range:
$13.48
$30.36
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
PIMCO Strategic Income Fund, XOMA Corporation, Another 2 Companies Have A High Estimated Dividend Yield - Via News Agency
Rhumbline Advisers Raises Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91 - Defense World
XOMA (NASDAQ:XOMA) Shares Pass Above 200-Day Moving Average of $25.91 - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Announces $0.52 Quarterly Dividend - Defense World
XOMA shares hold as analyst reiterates Buy rating post-FDA nod - Investing.com
XOMA Royalty gains FDA-approved asset for NPC By Investing.com - Investing.com Canada
XOMA shares hold as analyst reiterates Buy rating post-FDA nod - Investing.com Canada
XOMA Royalty gains FDA-approved asset for NPC - Investing.com
XOMAOXOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock Latest Stock News & Market Updates - StockTitan
XOMA shares hold as analyst reiterates Buy rating post-FDA nod - Investing.com India
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. - GlobeNewswire
Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC - TipRanks
XOMA Royalty gains FDA-approved asset for NPC By Investing.com - Investing.com UK
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) - Yahoo Finance
XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends - StockTitan
XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright - MarketBeat
Bank of New York Mellon Corp Has $1.48 Million Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
XOMA (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average of $25.74 - MarketBeat
XOMA (NASDAQ:XOMA) Stock Passes Above 200 Day Moving Average of $25.74 - Defense World
Head to Head Contrast: XOMA (NASDAQ:XOMAO) vs. Avid Bioservices (NASDAQ:CDMO) - Defense World
XOMA Co. (NASDAQ:XOMAO) Short Interest Up 180.0% in August - Defense World
Financial Survey: XOMA (NASDAQ:XOMA) and NanoViricides (NYSE:NNVC) - Defense World
XOMA Royalty to Present at Upcoming Investor Conferences in September - GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September - Yahoo Finance
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.53 - Defense World
XOMA (NASDAQ:XOMA) Shares Cross Above 200-Day Moving Average of $25.53 - MarketBeat
XOMA Co. (NASDAQ:XOMAO) Short Interest Up 400.0% in August - Defense World
XOMA (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average of $25.18 - MarketBeat
XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average of $25.18 - Defense World
Party Time: Brokers Just Made Major Increases To Their XOMA Royalty Corporation (NASDAQ:XOMA) Earnings Forecasts - Yahoo Finance
Price T Rowe Associates Inc. MD Invests $212,000 in XOMA Co. (NASDAQ:XOMA) - Defense World
HC Wainwright Weighs in on XOMA Co.'s Q3 2024 Earnings (NASDAQ:XOMA) - MarketBeat
XOMA Co. (NASDAQ:XOMA) to Post Q3 2024 Earnings of ($0.32) Per Share, HC Wainwright Forecasts - Defense World
Q3 2024 EPS Estimates for XOMA Co. (NASDAQ:XOMA) Boosted by Leerink Partnrs - Defense World
XOMA (NASDAQ:XOMA) Price Target Raised to $117.00 - MarketBeat
XOMA (NASDAQ:XOMA) Upgraded by StockNews.com to Hold - Defense World
XOMA shares price target raised on royalty growth prospects - Investing.com
XOMA Co. (NASDAQ:XOMA) Shares Sold by Vanguard Group Inc. - Defense World
XOMA shares price target raised on royalty growth prospects By Investing.com - Investing.com Canada
XOMA shares price target raised on royalty growth prospects - Investing.com India
XOMA shares price target raised on royalty growth prospects By Investing.com - Investing.com Australia
XOMA shares price target raised on royalty growth prospects By Investing.com - Investing.com UK
XOMA Royalty Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts - Simply Wall St
XOMA Royalty: Q2 Earnings Snapshot - Darien Times
XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $24.68 - Defense World
XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $24.68 - MarketBeat
XOMA Royalty: Q2 Earnings Snapshot - San Antonio Express-News
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):